Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AB928 + SRF617 + Zimberelimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AB928||AB 928|AB-928|Etrumadenant||Adenosine Targeting 19||AB928 (etrumadenant) is an antagonist of the adenosine receptors A2aR and A2bR, which may relieve adenosine-mediated immune suppression and lead to enhanced anti-tumor activity in combination with other agents (European Journal of Cancer, Vol 92, S14-S15, PMID: 30569245).|
|SRF617||SRF-617|SRF 617||CD39 Antibody 3||SRF617 is a monoclonal antibody that binds to CD39 and inhibits the conversion of ATP to AMP, potentially resulting in enhanced adaptive and innate immune response against tumor cells (NCI Thesaurus).|
|Zimberelimab||GLS-010|AB122|AB-122|GLS010||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 86||Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05177770||Phase II||AB928 + SRF617 + Zimberelimab||Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer||Recruiting||USA||0|